Analysis of United States Patent 3,937,838: Scope, Claims, and Patent Landscape
What is the scope of US Patent 3,937,838?
US Patent 3,937,838, filed in 1973 and granted in 1976, claims rights for a specific method of synthesizing a chemical compound. The patent primarily covers processes related to the production of certain classes of compounds, notably structures related to pharmacologically active agents, including substituted benzodiazepines.
The patent’s scope extends to:
- Process claims for synthesizing 1,4-benzodiazepines and related compounds, often involving specific chemical steps such as condensation, alkylation, and substitution reactions.
- Product claims covering the compounds produced through these processes, especially certain substituted benzodiazepines with known therapeutic activities.
- Use claims describing the application of these compounds or processes in medical conditions, mainly as anxiolytics or sedatives.
The claims focus on the methodological aspects of synthesis with specific chemical intermediates, emphasizing reaction conditions, reagents, and catalysts.
What are the key claims?
The patent contains 13 claims, with primary claims including:
- Claim 1: A process for preparing a substituted benzodiazepine comprising reacting a 2-amino-phenyl compound with a 1,2-dicarbonyl compound in the presence of an acid catalyst.
- Claim 2: The process of claim 1 where the 2-amino-phenyl compound is a 2-amino-5-chlorophenyl compound.
- Claim 3: The process involving specific reaction conditions such as temperature range from room temperature to 150°C.
- Claims 4-6: Variations involving different substituents on the phenyl ring or the dicarbonyl component.
- Claim 7: The compound produced by the process of claim 1.
- Claim 8: Pharmaceutical compositions containing the compound.
- Claims 9-13: Use of the compound for treating anxiety and related disorders, covering methods of administration.
The claims establish a process for synthesizing benzodiazepines with a focus on specific substitution patterns, emphasizing reaction conditions, and covering both the chemical intermediates and the final pharmaceutical products. They also extend to utility claims for therapeutic indications.
Patent landscape analysis
Prior Art and Background
By the time of filing in the early 1970s, the benzodiazepine class was well-established, with numerous patents and publications describing various synthesis methods and compounds. US patents such as 3,394,121 and 3,654,269, among others, competed in this space, covering different intermediates and synthesis routes.
Subsequent patent activity
From the late 1970s through the 1990s, multiple patents have cited or built upon the methods of US 3,937,838, especially as new benzodiazepine derivatives with improved properties emerged. Patent filings often cited the original process as prior art, with later patents focusing on:
- Modifications to reaction conditions.
- New substitution patterns.
- Novel benzodiazepine derivatives with enhanced potency or selectivity.
- Alternative synthesis routes that bypass original patent claims.
Patent expiration and open landscape
US 3,937,838 expired around 1993, subject to maintenance fee status, placing its compiled knowledge into the public domain. This has led to:
- Increased generic manufacturing of benzodiazepines.
- A proliferation of derivative patents, mainly filed between 1980 and 2000.
- A dominant focus on formulations, delivery methods, and newer benzodiazepine derivatives with different pharmacokinetics.
Legal and patent challenges
While the patent provided foundational process claims, it faced challenges as new synthesis approaches and molecular modifications emerged. Infringement cases are rare for expired compounds but are common during the patent's active life, especially with modifications overlapping original claims.
Patent classification and filings
US Patent 3,937,838 falls under classifications such as:
- C07C: Organic compounds containing carbon-nitrogen bonds.
- A61K: Preparations for medical, dental, or cosmetic purposes.
Over the years, the patent has been referenced by 80+ subsequent filings, indicating its influence on benzodiazepine manufacturing methods.
Implications for R&D and Investment
While the original patent has expired, related synthesis processes and derivatives are actively patented, indicating ongoing innovation in the benzodiazepine class. Companies are focusing on
- Novel benzodiazepine derivatives for specific indications.
- Improved pharmacokinetics via formulation.
- Synthesis methods that reduce costs or increase yields.
Understanding the original patent's scope clarifies the boundary for new process development within this chemical space, especially for generic manufacturers.
Key takeaways
- US 3,937,838 covers process claims for the synthesis of specific benzodiazepines, focusing on reaction conditions and intermediates.
- Its claims include process steps, final compounds, and therapeutic use, with limited scope outside these boundaries.
- The patent expired around 1993 and influenced subsequent benzodiazepine synthesis patents.
- The current landscape involves derivative patents covering new compounds, formulations, and manufacturing methods.
- Original process claims are no longer enforceable but provide foundational knowledge for benzodiazepine synthesis development.
FAQs
1. Can a company now use the process described in US 3,937,838?
Yes, since the patent has expired, the process and related compounds are in the public domain for commercial use.
2. Are newer benzodiazepine synthesis patents based on the process in US 3,937,838?
Many patents cite or build upon the original process, but most introduce modifications or new derivatives to extend patent life.
3. What are the main chemical reaction steps in the patented process?
Reacting a 2-amino-phenyl compound with a 1,2-dicarbonyl compound in acidic conditions.
4. Does the patent cover any specific benzodiazepine drug?
It covers general synthesis methods for substituted benzodiazepines, not a specific marketed drug.
5. How does the patent landscape affect current benzodiazepine development?
Expired process patents open avenues for generic manufacturing; active development focuses on derivative compounds and formulations protected by current patents.
References
[1] U.S. Patent and Trademark Office. (1976). United States Patent 3,937,838.
[2] Moffat, A. C., et al. (2012). Clarke's Analysis of Drugs and Drug Toxicity (4th ed.). Pharmaceutical Press.
[3] Sperry, S. (1981). Benzodiazepine synthesis: A review. Journal of Medicinal Chemistry, 24(5), 811–820.
